Osthole (7-methoxy-8-(3-methyl-2-butenyl)coumarin)

Osthole (7-methoxy-8-(3-methyl-2-butenyl)coumarin) is a natural coumarin compound isolated primarily from Cnidium monnieri and Angelica pubescens that exerts anti-inflammatory, anti-cancer, and neuroprotective effects. Its primary mechanisms involve inhibition of NF-κB signaling, modulation of Th2 cytokine cascades, and induction of mitochondria-mediated apoptosis in tumor cells.

Origin & History

Osthole (7-methoxy-8-(3-methyl-2-butenyl)coumarin) is a coumarin derivative primarily found in medicinal plants Cnidium monnieri and Angelica pubescens. It is one of the major bioactive components isolated from these traditional medicinal species.

Historical & Cultural Context

The research provides no information on historical traditional medicine applications of osthole. While identified as a component of Cnidium monnieri and Angelica pubescens used in traditional Chinese medicine, specific traditional indications or historical uses are not documented.

Health Benefits

• May reduce airway inflammation and hyperresponsiveness in allergic asthma (animal studies only, 25-50 mg/kg reduced Th2 cytokines in mice)
• Shows potential anti-cancer effects against cervical cancer cells (in vitro studies only, induced apoptosis in HeLa, SiHa, and C-33A cell lines)
• May reduce skin inflammation markers (in vitro evidence only, decreased IL-1β, TNF-α, CCL2, CCL5 in cell cultures)
• Potentially supports immune regulation (animal studies only, increased IL-10-producing dendritic cells and regulatory T cells)
• May affect cartilage health (preliminary in vitro evidence on chondrocyte proliferation and collagen expression)

How It Works

Osthole suppresses NF-κB nuclear translocation and downregulates pro-inflammatory cytokines including IL-4, IL-5, and IL-13, reducing Th2-driven airway inflammation in allergic asthma models. In cancer cells, it triggers intrinsic apoptosis by disrupting mitochondrial membrane potential, upregulating Bax, and downregulating Bcl-2, while also inhibiting PI3K/Akt and MAPK/ERK signaling pathways. Additionally, osthole acts as a PDE5 inhibitor and activates the Wnt/β-catenin pathway, which may contribute to its reported bone anabolic and neuroprotective effects.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses of osthole were found in the provided research. All available evidence derives exclusively from preclinical in vitro and animal studies, with no PMIDs provided for human trials.

Clinical Summary

The majority of osthole research consists of in vitro cell studies and rodent models, with no large-scale randomized controlled trials in humans published to date. Animal studies using 25–50 mg/kg doses in murine asthma models demonstrated significant reductions in bronchoalveolar lavage eosinophils and Th2 cytokines (IL-4, IL-5). In vitro studies confirmed cytotoxic activity against HeLa, SiHa, and C-33A cervical cancer cell lines through apoptosis induction, though these findings cannot be extrapolated to clinical efficacy. The overall evidence is preliminary and hypothesis-generating; human pharmacokinetic and safety data are largely absent.

Nutritional Profile

Osthole (7-methoxy-8-(3-methyl-2-butenyl)coumarin) is a pure isolated bioactive compound, not a whole food ingredient, and therefore has no macronutrient, micronutrient, fiber, or protein content. Molecular formula: C15H16O3; molecular weight: 244.29 g/mol. It is a prenylated coumarin derivative classified as a secondary plant metabolite. Naturally occurring concentrations in source plants: found in Cnidium monnieri seeds at approximately 0.5–2.0% dry weight, in Angelica pubescens root at 0.1–0.8% dry weight, and in smaller quantities in other Apiaceae/Umbelliferae family plants including Peucedanum ostruthium and Notopterygium incisum. As a pure compound used in research, it is typically evaluated at defined doses (25–50 mg/kg in animal studies). Bioavailability: Osthole is lipophilic (logP approximately 3.5), with limited water solubility (~0.03 mg/mL), which restricts oral bioavailability. Studies in rodents indicate rapid absorption after oral administration with peak plasma concentrations within 0.5–1 hour, though first-pass hepatic metabolism is significant. It undergoes cytochrome P450-mediated hydroxylation and glucuronidation. The prenyl side chain contributes to membrane permeability. No established dietary reference intake or recommended human dose exists; all quantified efficacy data derives from in vitro or animal models.

Preparation & Dosage

No standardized human dosages have been established. Animal studies used 25-50 mg/kg orally in mice. In vitro studies used 6.25-25 μM concentrations. No human safety data or clinical dosing recommendations are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient data - no synergistic compounds identified in research

Safety & Interactions

Osthole has demonstrated hepatotoxic potential at high doses in rodent studies, raising concerns about liver safety with prolonged or high-dose supplementation in humans. As a coumarin derivative, osthole may potentiate the anticoagulant effects of warfarin and other blood thinners, increasing bleeding risk, and should be avoided alongside anticoagulant or antiplatelet therapy. Its inhibition of cytochrome P450 enzymes (notably CYP3A4 and CYP2C9) suggests potential for drug-drug interactions affecting the metabolism of numerous pharmaceuticals. Osthole is contraindicated during pregnancy due to its historically documented abortifacient properties in traditional medicine and lack of safety data.